INT209027

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.14
First Reported 2007
Last Reported 2009
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 7
Disease Relevance 2.41
Pain Relevance 2.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

transport (Slc11a1) plasma membrane (Slc11a1) lysosome (Slc11a1)
Anatomy Link Frequency
immune cells 2
Slc11a1 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 98 97.92 Very High Very High Very High
cytokine 168 95.68 Very High Very High Very High
chemokine 46 90.20 High High
headache 5 88.32 High High
pruritus 5 83.28 Quite High
Pain 5 78.64 Quite High
Inflammatory response 14 28.64 Quite Low
Inflammatory stimuli 14 5.00 Very Low Very Low Very Low
interstitial cystitis 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
INFLAMMATION 126 97.92 Very High Very High Very High
Myalgia 5 92.48 High High
Headache 5 88.32 High High
Pruritus 5 83.28 Quite High
Pain 5 78.64 Quite High
Granuloma 22 37.60 Quite Low
Increased Venous Pressure Under Development 4 18.96 Low Low
Pressure And Volume Under Development 20 16.64 Low Low
Cystitis 8 11.08 Low Low
Hypersensitivity 13 5.40 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
These findings suggest that the therapeutic effects of BCG are due in part to the rapid accumulation of antigen presenting, and activated immune cells that are responsible for the production of a multiphasic immune response as demonstrated by the presence of TH1 (IFN-?
Positive_regulation (due) of Positive_regulation (effects) of BCG in immune cells
1) Confidence 0.14 Published 2007 Journal BMC Immunol Section Body Doc Link PMC1891101 Disease Relevance 0.31 Pain Relevance 0.40
However, IL-17 was induced primarily in response to BCG (Figure 9).
Positive_regulation (induced) of Positive_regulation (response) of BCG
2) Confidence 0.14 Published 2007 Journal BMC Immunol Section Body Doc Link PMC1891101 Disease Relevance 0.41 Pain Relevance 0.75
BCG-MVA85A induced significantly stronger cellular immune responses to antigen 85 protein and antigen 85A SPP than BCG-BCG vaccination
Positive_regulation (induced) of Positive_regulation (responses) of BCG
3) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2694271 Disease Relevance 0.34 Pain Relevance 0.21
BCG-MVA85A induced significantly stronger cellular immune responses to antigen 85 protein and antigen 85A SPP than BCG-BCG vaccination
Positive_regulation (responses) of Positive_regulation (vaccination) of BCG
4) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2694271 Disease Relevance 0.34 Pain Relevance 0.21
BCG-MVA85A induced significantly stronger cellular immune responses to antigen 85 protein and antigen 85A SPP than BCG-BCG vaccination
Positive_regulation (responses) of Positive_regulation (than) of BCG
5) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2694271 Disease Relevance 0.33 Pain Relevance 0.20
BCG-MVA85A induced significantly stronger cellular immune responses to antigen 85 protein and antigen 85A SPP than BCG-BCG vaccination
Positive_regulation (induced) of Positive_regulation (responses) of BCG
6) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2694271 Disease Relevance 0.34 Pain Relevance 0.21
BCG-MVA85A induced significantly stronger cellular immune responses to antigen 85 protein and antigen 85A SPP than BCG-BCG vaccination
Positive_regulation (responses) of Positive_regulation (vaccination) of BCG
7) Confidence 0.05 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2694271 Disease Relevance 0.33 Pain Relevance 0.20

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox